How To Use HCPCS Code C9483

HCPCS code C9483 describes an injection of atezolizumab, with a dosage of 10 mg. This code is used to identify the administration of this specific medication in medical coding and billing processes. In this article, we will explore the details of HCPCS code C9483, including its official description, procedure, when to use it, billing guidelines, historical information, Medicare and insurance coverage, and provide examples of when this code should be billed.

1. What is HCPCS C9483?

HCPCS code C9483 is a specific code used to identify the injection of atezolizumab, with a dosage of 10 mg. It is an alphanumeric code that is part of the Healthcare Common Procedure Coding System (HCPCS). This code is essential for medical coders and billers to accurately document and bill for the administration of this medication.

2. Official Description

The official description of HCPCS code C9483 is “Injection, atezolizumab, 10 mg.” This description provides a concise and standardized way to identify the specific procedure or service associated with this code. The short description for this code is “Enteral supp not otherwise c,” which indicates that it is related to enteral support.

3. Procedure

1. Prepare the necessary equipment and supplies for administering the injection.
2. Verify the patient’s identity and confirm the prescribed dosage of atezolizumab.
3. Cleanse the injection site with an appropriate antiseptic solution.
4. Prepare the atezolizumab injection according to the manufacturer’s instructions.
5. Administer the injection using the appropriate technique and route of administration.
6. Observe the patient for any immediate adverse reactions or complications.
7. Document the administration of atezolizumab, including the dosage, route, and any relevant patient information.

4. When to use HCPCS code C9483

HCPCS code C9483 should be used when documenting and billing for the injection of atezolizumab with a dosage of 10 mg. It is important to use this code accurately and in the appropriate context to ensure proper reimbursement and tracking of this specific procedure. Medical coders and billers should follow any specific eligibility criteria or guidelines provided by payers or regulatory bodies when using this code.

5. Billing Guidelines and Documentation Requirements

When using HCPCS code C9483, healthcare providers need to document the administration of atezolizumab, including the dosage, route of administration, and any relevant patient information. It is crucial to accurately record the details of the procedure to support proper billing and reimbursement. Providers should also ensure that they follow any specific billing guidelines or requirements set forth by payers or regulatory bodies.

6. Historical Information and Code Maintenance

HCPCS code C9483 was added to the Healthcare Common Procedure Coding System on January 01, 1985. It has an effective date of January 01, 1996. This code has a pricing indicator code of 57, which indicates that it is priced by other carriers. The multiple pricing indicator code for this code is A, which means it is not applicable as HCPCS priced under one methodology. There have been no maintenance actions taken for this code, as indicated by the action code N, which means no maintenance for this code.

7. Medicare and Insurance Coverage

Medicare and insurance coverage for HCPCS code C9483 may vary. Providers should refer to the Medicare Carriers Manual Reference Section Number 2130 for specific information regarding coverage and reimbursement. It is important to understand the pricing indicator code and multiple pricing indicator code associated with this code to determine how it is priced by Medicare or other insurers.

8. Examples

Here are five examples of when HCPCS code C9483 should be billed:

1. A patient with a diagnosis of lung cancer receives an injection of atezolizumab, 10 mg, as part of their chemotherapy regimen.
2. An oncology clinic administers atezolizumab, 10 mg, to a patient with advanced bladder cancer.
3. A hospital-based infusion center provides an atezolizumab injection, 10 mg, to a patient with metastatic breast cancer.
4. A physician’s office administers atezolizumab, 10 mg, to a patient with locally advanced or metastatic non-small cell lung cancer.
5. A healthcare provider administers atezolizumab, 10 mg, to a patient with triple-negative breast cancer as part of their treatment plan.